Immune-Onc Therapeutics, Inc.(“Immune-Onc”), a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients, announced today the publication of a study in Nature https://www.nature.com/articles/s41586-018-0615-z that provides new insights into immune regulation and the progression of acute myeloid leukemia (AML).The study, led by The University of Texas Southwestern Medical Center (“UT Southwestern”) and The University of Texas Health Science Center at Houston (“UTHealth”), demonstrated that leukocyte immunoglobulin-like receptor B4 (LILRB4), an immune inhibitory receptor, orchestrates leukemia invasion pathways by creating an immune suppressive microenvironment. Researchers discovered that blocking LILRB4 signaling with antagonistic antibodies can impede AML development in preclinical models, making it a compelling therapeutic target.
Founded in 2016, Immune-Onc has raised $40 million. Immune-Onc Therapeutics is a newly established bio-pharmaceutical company that focuses on developing innovative therapeutic antibodies for cancer treatment. The company applies the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients.
Dr. Cheng Cheng “Alec” Zhang, Professor of Physiology